Boehringer Ingelheim & Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers: Ingelheim, Germany Thursday, April 24, 2025, 15 ...

Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a ...

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer ...

New Survey Shows That Over 90% of Animal Owners Trust and Appreciate Veterinary Teams but Underestimate the Demands of the Profession ...

Pharmaceutical Technology is the independent source for information, insight, and analysis on bio/pharmaceutical formulation, development, and manufacturing.

German family-owned pharma major Boehringer Ingelheim and Dutch precision oncology company Tessellate Bio have entered into a ...

Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality ...

Boehringer Ingelheim and Tessellate Bio form a €500m partnership to develop precision therapies targeting ALT-positive ...

Company prepares new product launches starting in 2025.

At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address ...

The "Enterprise Tech Ecosystem Series: Boehringer Ingelheim 2025" company profile has been added to ResearchAndMarkets.com's offering. Boehringer Ingelheim International: Leading the Way in ...